Platelets, circulating tumor cells, and the circulome

1.

Zernecke, A., Bidzhekov, K., Noels, H., Shagdarsuren, E., Gan, L., Denecke, B., et al. (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Science Signaling, 2(100) ra81 doi:10.1126/scisignal.2000610.

2.

Ribeiro, M. F., Zhu, H., Millard, R. W., & Fan, G. C. (2013). Exosomes function in pro- and anti-angiogenesis. Curr Angiogenes, 2(1), 54–59. doi:10.2174/22115528113020020001.PubMedPubMedCentral

3.

Zhang, Y., Liu, D., Chen, X., Li, J., Li, L., Bian, Z., et al. (2010). Secreted monocytic miR-150 enhances targeted endothelial cell migration. Molecular Cell, 39(1), 133–144. doi:10.1016/j.molcel.2010.06.010.PubMedCrossRef

4.

Pulliam, L., & Gupta, A. (2015). Modulation of cellular function through immune-activated exosomes. DNA and Cell Biology, 34(7), 459–463. doi:10.1089/dna.2015.2884.PubMedPubMedCentralCrossRef

5.

Rak, J. (2013). Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Frontiers in Pharmacology, 4, 21. doi:10.3389/fphar.2013.00021.PubMedPubMedCentralCrossRef

6.

Azmi, A. S., Bao, B., & Sarkar, F. H. (2013). Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Reviews, 32(3–4), 623–642. doi:10.1007/s10555-013-9441-9.PubMedCrossRef

7.

Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J., et al. (2015). Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics, Proteomics & Bioinformatics, 13(1), 17–24. doi:10.1016/j.gpb.2015.02.001.CrossRef

8.

Lopes-Rodrigues, V., Di Luca, A., Sousa, D., Seca, H., Meleady, P., Henry, M., et al. (2016). Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells. Biochimica et Biophysica Acta, 1860(3), 618–627. doi:10.1016/j.bbagen.2015.12.011.PubMedCrossRef

9.

Ciardiello, C., Cavallini, L., Spinelli, C., Yang, J., Reis-Sobreiro, M., de Candia, P., et al. (2016). Focus on extracellular vesicles: new frontiers of cell-to-cell communication in cancer. International Journal of Molecular Sciences, 17(2). doi:10.3390/ijms17020175.

10.

Yu, S., Cao, H., Shen, B., Feng, J. (2015). Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget, 6(35), 37151–37168, doi:10.18632/oncotarget.6022.

11.

Davila, M., Robles-Carrillo, L., Unruh, D., Huo, Q., Gardiner, C., Sargent, I. L., et al. (2014). Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation? Journal of Thrombosis and Haemostasis, 12(2), 186–196. doi:10.1111/jth.12475.PubMedCrossRef

12.

Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., et al. (2015). Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. doi:10.1038/nature14581.

13.

Thakur, B. K., Zhang, H., Becker, A., Matei, I., Huang, Y., Costa-Silva, B., et al. (2014). Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Research, 24(6), 766–769. doi:10.1038/cr.2014.44.PubMedPubMedCentralCrossRef

14.

Botti, G., Marra, L., Malzone, M. G., Anniciello, A., Botti, C., Franco, R., et al. (2017). LncRNA HOTAIR as prognostic circulating marker and potential therapeutic target in patients with tumor diseases. Current Drug Targets. 18(1), 27-34.

15.

Fesler, A., Jiang, J., Zhai, H., & Ju, J. (2014). Circulating microRNA testing for the early diagnosis and follow-up of colorectal cancer patients. Molecular Diagnosis & Therapy, 18(3), 303–308. doi:10.1007/s40291-014-0089-0.CrossRef

16.

Huang, X., Yuan, T., Tschannen, M., Sun, Z., Jacob, H., Du, M., et al. (2013). Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics, 14, 319. doi:10.1186/1471-2164-14-319.PubMedPubMedCentralCrossRef

17.

Khan, N., Mironov, G., & Berezovski, M. V. (2016). Direct detection of endogenous microRNAs and their post-transcriptional modifications in cancer serum by capillary electrophoresis-mass spectrometry. Analytical and Bioanalytical Chemistry. doi:10.1007/s00216-015-9277-y.

18.

Silva, A., Bullock, M., & Calin, G. (2015). The clinical relevance of long non-coding RNAs in cancer. Cancers (Basel), 7(4), 2169–2182. doi:10.3390/cancers7040884.CrossRef

19.

Mandel, P., & Metais, P. (1948). Not Available. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales, 142(3–4), 241–243.PubMed

20.

Heitzer, E., Ulz, P., & Geigl, J. B. (2015). Circulating tumor DNA as a liquid biopsy for cancer. Clinical Chemistry, 61(1), 112–123. doi:10.1373/clinchem.2014.222679.PubMedCrossRef

21.

Ulz, P., Auer, M., & Heitzer, E. (2016). Detection of circulating tumor DNA in the blood of cancer patients: an important tool in cancer chemoprevention. Methods in Molecular Biology, 1379, 45–68. doi:10.1007/978-1-4939-3191-0_5.PubMedCrossRef

22.

Warton, K., & Samimi, G. (2015). Methylation of cell-free circulating DNA in the diagnosis of cancer. Frontiers in Molecular Biosciences, 2, 13. doi:10.3389/fmolb.2015.00013.PubMedPubMedCentralCrossRef

23.

Beljanski, M., & Plawecki, M. (1979). Particular RNA fragments as promoters of leukocyte and platelet formation in rabbits. Experimental Cell Biology, 47(3), 218–225.PubMed

24.

Korosteleva, T. A., & Chistiakova, Z. M. (1979). Immunological study of rat liver RNA in the early stages of hepatic carcinogenesis. Voprosy Onkologii, 25(8), 77–81.PubMed

25.

Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkaran, B., Liggins, A. P., Pulford, K., et al. (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British Journal of Haematology, 141(5), 672–675. doi:10.1111/j.1365-2141.2008.07077.x.PubMedCrossRef

26.

Chim, S. S., Shing, T. K., Hung, E. C., Leung, T. Y., Lau, T. K., Chiu, R. W., et al. (2008). Detection and characterization of placental microRNAs in maternal plasma. Clinical Chemistry, 54(3), 482–490. doi:10.1373/clinchem.2007.097972.PubMedCrossRef

27.

Spindler, K. L., Pallisgaard, N., Andersen, R. F., Brandslund, I., & Jakobsen, A. (2015). Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PloS One, 10(4), e0108247. doi:10.1371/journal.pone.0108247.PubMedPubMedCentralCrossRef

28.

Bryzgunova, O. E., & Laktionov, P. P. (2015). Generation of blood circulating DNA: the sources, peculiarities of circulation and structure. Biomeditsinskaya Khimiya, 61(4), 409–426. doi:10.18097/PBMC20156104409.CrossRef

29.

Vasilyeva, L. N., Podgornaya, O. I., & Bespalov, V. G. (2015). Nucleosome fracton of extracellular dna as the index of apoptosis. Tsitologiia, 57(2), 87–94.PubMed

30.

Wissler, J. H., Wissler, J. E., & Logemann, E. (2008). Extracellular functional noncoding nucleic acid bioaptamers and angiotropin RNP ribokines in vascularization and self-tolerance. Annals of the New York Academy of Sciences, 1137, 316–342. doi:10.1196/annals.1448.047.PubMedCrossRef

31.

Molnar, B., Toth, K., Bartak, B. K., & Tulassay, Z. (2015). Plasma methylated septin 9: a colorectal cancer screening marker. Expert Review of Molecular Diagnostics, 15(2), 171–184. doi:10.1586/14737159.2015.975212.PubMedCrossRef

32.

Patai, A. V., Valcz, G., Hollosi, P., Kalmar, A., Peterfia, B., Patai, A., et al. (2015). Comprehensive DNA methylation analysis reveals a common ten-gene methylation signature in colorectal adenomas and carcinomas. PloS One, 10(8), e0133836. doi:10.1371/journal.pone.0133836.PubMedPubMedCentralCrossRef

33.

Hao, T. B., Shi, W., Shen, X. J., Qi, J., Wu, X. H., Wu, Y., et al. (2014). Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. British Journal of Cancer, 111(8), 1482–1489. doi:10.1038/bjc.2014.470.PubMedPubMedCentralCrossRef

34.

Tie, J., Kinde, I., Wang, Y., Wong, H. L., Roebert, J., Christie, M., et al. (2015). Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Annals of Oncology, 26(8), 1715–1722. doi:10.1093/annonc/mdv177.PubMedPubMedCentralCrossRef

35.

Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014). Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Reviews, 33(1), 231–269. doi:10.1007/s10555-014-9498-0.PubMedPubMedCentralCrossRef

36.

Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., et al. (2015). Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PloS One, 10(10), e0140712. doi:10.1371/journal.pone.0140712.PubMedPubMedCentralCrossRef

37.

Jovelet, C., Ileana, E., Le Deley, M. C., Motte, N., Rosellini, S., Romero, A., et al. (2016). Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial. Clinical Cancer Research. doi:10.1158/1078-0432.CCR-15-2470.

38.

Kalia, M. (2015). Biomarkers for personalized oncology: recent advances and future challenges. Metabolism, 64(3 Suppl 1), S16–S21. doi:10.1016/j.metabol.2014.10.027.PubMedCrossRef

39.

Patel, K. M., & Tsui, D. W. (2015). The translational potential of circulating tumour DNA in oncology. Clinical Biochemistry, 48(15), 957–961. doi:10.1016/j.clinbiochem.2015.04.005.PubMedCrossRef

40.

Kensler, T. W., Spira, A., Garber, J. E., Szabo, E., Lee, J. J., Dong, Z., et al. (2016). Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prevention Research (Philadelphia, Pa.), 9(1), 2–10. doi:10.1158/1940-6207.CAPR-15-0406.CrossRef

41.

Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., et al. (2016). Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discovery, 6(2), 147–153. doi:10.1158/2159-8290.CD-15-1283.PubMedCrossRef

42.

Santiago-Walker, A., Gagnon, R., Mazumdar, J., Casey, M., Long, G. V., Schadendorf, D., et al. (2016). Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clinical Cancer Research, 22(3), 567–574. doi:10.1158/1078-0432.CCR-15-0321.PubMedCrossRef

43.

Zill, O. A., Greene, C., Sebisanovic, D., Siew, L. M., Leng, J., Vu, M., et al. (2015). Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discovery, 5(10), 1040–1048. doi:10.1158/2159-8290.CD-15-0274.PubMedPubMedCentralCrossRef

44.

Bratman, S. V., Newman, A. M., Alizadeh, A. A., & Diehn, M. (2015). Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Review of Molecular Diagnostics, 15(6), 715–719. doi:10.1586/14737159.2015.1019476.PubMedPubMedCentral

45.

Reinert, T., Scholer, L. V., Thomsen, R., Tobiasen, H., Vang, S., Nordentoft, I., et al. (2015). Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. doi:10.1136/gutjnl-2014-308859.

46.

Thress, K. S., Brant, R., Carr, T. H., Dearden, S., Jenkins, S., Brown, H., et al. (2015). EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer, 90(3), 509–515. doi:10.1016/j.lungcan.2015.10.004.PubMedCrossRef

47.

Richardson, A. L., & Iglehart, J. D. (2012). BEAMing up personalized medicine: mutation detection in blood. Clinical Cancer Research, 18(12), 3209–3211. doi:10.1158/1078-0432.CCR-12-0871.PubMedPubMedCentralCrossRef

48.

Castellanos-Rizaldos, E., Paweletz, C., Song, C., Oxnard, G. R., Mamon, H., Janne, P. A., et al. (2015). Enhanced ratio of signals enables digital mutation scanning for rare allele detection. The Journal of Molecular Diagnostics, 17(3), 284–292. doi:10.1016/j.jmoldx.2014.12.003.PubMedPubMedCentralCrossRef

49.

Tost, J. (2016). The clinical potential of Enhanced-ice-COLD-PCR. Expert Review of Molecular Diagnostics, 16(3), 265–268. doi:10.1586/14737159.2016.1123623.PubMedCrossRef

50.

Yuan, H., Zhu, Z. Z., Lu, Y., Liu, F., Zhang, W., Huang, G., et al. (2012). A modified extraction method of circulating free DNA for epidermal growth factor receptor mutation analysis. Yonsei Medical Journal, 53(1), 132–137. doi:10.3349/ymj.2012.53.1.132.PubMedCrossRef

51.

Bell, D. A., & Morrison, B. (1991). The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clinical Immunology and Immunopathology, 60(1), 13–26.PubMedCrossRef

52.

Vasil'eva, I. N., & Zinkin, V. N. (2013). The value of low-molecular-weight DNA of blood plasma in the diagnostic of the patological processes of different genesis. Biomeditsinskaya Khimiya, 59(3), 358–373.CrossRef

53.

Wyllie, A. H. (1980). Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature, 284(5756), 555–556.PubMedCrossRef

54.

Chandrananda, D., Thorne, N. P., & Bahlo, M. (2015). High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. BMC Medical Genomics, 8, 29. doi:10.1186/s12920-015-0107-z.PubMedPubMedCentralCrossRef

55.

Cai, X., Janku, F., Zhan, Q., & Fan, J. B. (2015). Accessing genetic information with liquid biopsies. Trends in Genetics, 31(10), 564–575. doi:10.1016/j.tig.2015.06.001.PubMedCrossRef

56.

Sequist, L. V., Soria, J. C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., et al. (2015). Rociletinib in EGFR-mutated non-small-cell lung cancer. The New England Journal of Medicine, 372(18), 1700–1709. doi:10.1056/NEJMoa1413654.PubMedCrossRef

57.

Schiavon, G., Hrebien, S., Garcia-Murillas, I., Cutts, R. J., Pearson, A., Tarazona, N., et al. (2015). Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Science Translational Medicine, 7(313), 313ra182. doi:10.1126/scitranslmed.aac7551.PubMedPubMedCentralCrossRef

58.

Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. (2014). Clinical relevance of circulating cell-free microRNAs in cancer. Nature Reviews. Clinical Oncology, 11(3), 145–156. doi:10.1038/nrclinonc.2014.5.PubMedCrossRef

59.

Sun, Y., Liu, Y., Cogdell, D., Calin, G. A., Sun, B., Kopetz, S., et al. (2016). Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget. doi:10.18632/oncotarget.7196.

60.

Igaz, I., & Igaz, P. (2015). Diagnostic relevance of microRNAs in other body fluids including urine, feces, and saliva. EXS, 106, 245–252. doi:10.1007/978-3-0348-0955-9_11.PubMed

61.

Qin, J., Williams, T. L., & Fernando, M. R. (2013). A novel blood collection device stabilizes cell-free RNA in blood during sample shipping and storage. BMC Research Notes, 6, 380. doi:10.1186/1756-0500-6-380.PubMedPubMedCentralCrossRef

62.

Zuo, Z., Maiti, S., Hu, S., Loghavi, S., Calin, G. A., Garcia-Manero, G., et al. (2015). Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern Pathology, 28(3), 373–382. doi:10.1038/modpathol.2014.108.PubMedCrossRef

63.

Alder, H., Taccioli, C., Chen, H., Jiang, Y., Smalley, K. J., Fadda, P., et al. (2012). Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. Carcinogenesis, 33(9), 1736–1744. doi:10.1093/carcin/bgs204.PubMedPubMedCentralCrossRef

64.

Vickovic, S., Ahmadian, A., Lewensohn, R., & Lundeberg, J. (2015). Toward rare blood cell preservation for RNA sequencing. The Journal of Molecular Diagnostics, 17(4), 352–359. doi:10.1016/j.jmoldx.2015.03.009.PubMedCrossRef

65.

Liu, H. S., & Xiao, H. S. (2014). MicroRNAs as potential biomarkers for gastric cancer. World Journal of Gastroenterology, 20(34), 12007–12017. doi:10.3748/wjg.v20.i34.12007.PubMedPubMedCentralCrossRef

66.

Mego, M., Cholujova, D., Minarik, G., Sedlackova, T., Gronesova, P., Karaba, M., et al. (2016). CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer. BMC Cancer, 16(1), 127. doi:10.1186/s12885-016-2143-2.PubMedPubMedCentralCrossRef

67.

Wozniak, M. B., Scelo, G., Muller, D. C., Mukeria, A., Zaridze, D., & Brennan, P. (2015). Circulating MicroRNAs as non-invasive biomarkers for early detection of non-small-cell lung cancer. PloS One, 10(5), e0125026. doi:10.1371/journal.pone.0125026.PubMedPubMedCentralCrossRef

68.

Grun, D., Lyubimova, A., Kester, L., Wiebrands, K., Basak, O., Sasaki, N., et al. (2015). Single-cell messenger RNA sequencing reveals rare intestinal cell types. Nature, 525(7568), 251–255. doi:10.1038/nature14966.PubMedCrossRef

69.

Zhang, J., Zhang, K., Bi, M., Jiao, X., Zhang, D., & Dong, Q. (2014). Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anti-Cancer Drugs, 25(3), 346–352. doi:10.1097/CAD.0000000000000049.PubMedCrossRef

70.

Pucciarelli, S., Rampazzo, E., Briarava, M., Maretto, I., Agostini, M., Digito, M., et al. (2012). Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Annals of Surgical Oncology, 19(9), 3089–3096. doi:10.1245/s10434-012-2272-z.PubMedCrossRef

71.

Verma, A. M., Patel, M., Aslam, M. I., Jameson, J., Pringle, J. H., Wurm, P., et al. (2015). Circulating plasma microRNAs as a screening method for detection of colorectal adenomas. Lancet, 385(Suppl 1), S100. doi:10.1016/S0140-6736(15)60415-9.PubMedCrossRef

72.

Kishikawa, T., Otsuka, M., Ohno, M., Yoshikawa, T., Takata, A., & Koike, K. (2015). Circulating RNAs as new biomarkers for detecting pancreatic cancer. World Journal of Gastroenterology, 21(28), 8527–8540. doi:10.3748/wjg.v21.i28.8527.PubMedPubMedCentralCrossRef

73.

Lindner, K., Haier, J., Wang, Z., Watson, D. I., Hussey, D. J., & Hummel, R. (2015). Circulating microRNAs: emerging biomarkers for diagnosis and prognosis in patients with gastrointestinal cancers. Clinical Science (London, England), 128(1), 1–15. doi:10.1042/CS20140089.CrossRef

74.

Alsidawi, S., Malek, E., & Driscoll, J. J. (2014). MicroRNAs in brain metastases: potential role as diagnostics and therapeutics. International Journal of Molecular Sciences, 15(6), 10508–10526. doi:10.3390/ijms150610508.PubMedPubMedCentralCrossRef

75.

Wulfken, L. M., Moritz, R., Ohlmann, C., Holdenrieder, S., Jung, V., Becker, F., et al. (2011). MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PloS One, 6(9), e25787. doi:10.1371/journal.pone.0025787.PubMedPubMedCentralCrossRef

76.

Pigati, L., Yaddanapudi, S. C., Iyengar, R., Kim, D. J., Hearn, S. A., Danforth, D., et al. (2010). Selective release of microRNA species from normal and malignant mammary epithelial cells. PloS One, 5(10), e13515. doi:10.1371/journal.pone.0013515.PubMedPubMedCentralCrossRef

77.

Chakraborty, C., & Das, S. (2016). Profiling cell-free and circulating miRNA: a clinical diagnostic tool for different cancers. Tumour Biology. doi:10.1007/s13277-016-4907-3.

78.

Lopez-Vilchez, I., Diaz-Ricart, M., Galan, A. M., Roque, M., Caballo, C., Molina, P., et al. (2016). Internalization of tissue factor-rich microvesicles by platelets occurs independently of GPIIb-IIIa, and involves CD36 receptor, serotonin transporter and cytoskeletal assembly. Journal of Cellular Biochemistry, 117(2), 448–457. doi:10.1002/jcb.25293.PubMedCrossRef

79.

Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., et al. (2012). Paraneoplastic thrombocytosis in ovarian cancer. The New England Journal of Medicine, 366(7), 610–618. doi:10.1056/NEJMoa1110352.PubMedPubMedCentralCrossRef

80.

Thon, J. N., & Italiano, J. E. (2010). Platelet formation. Seminars in Hematology, 47(3), 220–226. doi:10.1053/j.seminhematol.2010.03.005.PubMedPubMedCentralCrossRef

81.

Agam, G., Bessler, H., & Djaldetti, M. (1976). In vitro DNA and RNA synthesis by human platelets. Biochimica et Biophysica Acta, 425(1), 41–48.PubMedCrossRef

82.

Macaulay, I. C., Carr, P., Gusnanto, A., Ouwehand, W. H., Fitzgerald, D., & Watkins, N. A. (2005). Platelet genomics and proteomics in human health and disease. The Journal of Clinical Investigation, 115(12), 3370–3377. doi:10.1172/jci26885.PubMedPubMedCentralCrossRef

83.

Italiano Jr., J. E., & Shivdasani, R. A. (2003). Megakaryocytes and beyond: the birth of platelets. Journal of Thrombosis and Haemostasis, 1(6), 1174–1182.PubMedCrossRef

84.

Gnatenko, D. V., Dunn, J. J., Schwedes, J., & Bahou, W. F. (2009). Transcript profiling of human platelets using microarray and serial analysis of gene expression (SAGE). Methods in Molecular Biology, 496, 245–272. doi:10.1007/978-1-59745-553-4_16.PubMedCrossRef

85.

Denis, M. M., Tolley, N. D., Bunting, M., Schwertz, H., Jiang, H., Lindemann, S., et al. (2005). Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell, 122(3), 379–391. doi:10.1016/j.cell.2005.06.015.PubMedPubMedCentralCrossRef

86.

Kieffer, N., Guichard, J., Farcet, J. P., Vainchenker, W., & Breton-Gorius, J. (1987). Biosynthesis of major platelet proteins in human blood platelets. European Journal of Biochemistry, 164(1), 189–195.PubMedCrossRef

87.

Arimori, S., & Sumitomo, K. (1978). Ultrastructural observation of openings of open canalicular system on the membrane surface of human platelet by freeze-etching method (author’s transl). Nihon Ketsueki Gakkai Zasshi, 41(3), 569–572.PubMed

88.

White, J. G. (1972). Uptake of latex particles by blood platelets: phagocytosis or sequestration? The American Journal of Pathology, 69(3), 439–458.PubMedPubMedCentral

89.

Thon, J. N., & Italiano, J. E. (2012). Platelets: production, morphology and ultrastructure. Handbook of Experimental Pharmacology, 210, 3–22. doi:10.1007/978-3-642-29423-5_1.CrossRef

90.

van Nispen tot Pannerden, H., de Haas, F., Geerts, W., Posthuma, G., van Dijk, S., & Heijnen, H. F. (2010). The platelet interior revisited: electron tomography reveals tubular alpha-granule subtypes. Blood, 116(7), 1147–1156. doi:10.1182/blood-2010-02-268680.PubMedCrossRef

91.

Choi, W., Karim, Z. A., & Whiteheart, S. W. (2010). Protein expression in platelets from six species that differ in their open canalicular system. Platelets, 21(3), 167–175. doi:10.3109/09537101003611385.PubMedPubMedCentralCrossRef

92.

Hughes, F. B., & Brodie, B. B. (1959). The mechanism of serotonin and catecholamine uptake by platelets. The Journal of Pharmacology and Experimental Therapeutics, 127, 96–102.PubMed

93.

Adnot, S., Houssaini, A., Abid, S., Marcos, E., & Amsellem, V. (2013). Serotonin transporter and serotonin receptors. Handbook of Experimental Pharmacology, 218, 365–380. doi:10.1007/978-3-642-38664-0_15.PubMedCrossRef

94.

Pavanetto, M., Zarpellon, A., Borgo, C., Donella-Deana, A., & Deana, R. (2011). Regulation of serotonin transport in human platelets by tyrosine kinase Syk. Cellular Physiology and Biochemistry, 27(2), 139–148. doi:10.1159/000325216.PubMedCrossRef

95.

Jin, K., Li, T., van Dam, H., Zhou, F., & Zhang, L. (2017). Molecular insights into tumour metastasis: tracing the dominant events. The Journal of Pathology, 241(5), 567–577. doi:10.1002/path.4871.PubMedCrossRef

96.

Mitrugno, A., Tormoen, G. W., Kuhn, P., & McCarty, O. J. (2016). The prothrombotic activity of cancer cells in the circulation. Blood Reviews, 30(1), 11–19. doi:10.1016/j.blre.2015.07.001.PubMedCrossRef

97.

Hisada, Y., Geddings, J. E., Boulaftali, Y., Getz, T. M., Whelihan, M., Fuentes, R., et al. (2016). OC-04—tissue factor positive microvesicles activate platelets in vitro and in vivo and enhance thrombosis in mice. Thrombosis Research, 140(Suppl 1), S169–S170. doi:10.1016/S0049-3848(16)30121-9.PubMedCrossRef

98.

Geddings, J. E., Hisada, Y., Boulaftali, Y., Getz, T. M., Whelihan, M., Fuentes, R., et al. (2016). Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. Journal of Thrombosis and Haemostasis, 14(1), 153–166. doi:10.1111/jth.13181.PubMedCrossRef

99.

Tseng, J. C., Chang, L. C., Jiang, B. Y., Liu, Y. C., Chen, H. J., Yu, C. T., et al. (2014). Elevated circulating levels of tissue factor-positive microvesicles are associated with distant metastasis in lung cancer. Journal of Cancer Research and Clinical Oncology, 140(1), 61–67. doi:10.1007/s00432-013-1544-8.PubMedCrossRef

100.

Heijnen, H., & van der Sluijs, P. (2015). Platelet secretory behaviour: as diverse as the granules ... or not? Journal of Thrombosis and Haemostasis, 13(12), 2141–2151. doi:10.1111/jth.13147.PubMedCrossRef

101.

Chen, C. H., Lo, R. W., Urban, D., Pluthero, F. G., & Kahr, W. H. (2017). Alpha-granule biogenesis: from disease to discovery. Platelets, 28(2), 147–154. doi:10.1080/09537104.2017.1280599.PubMedCrossRef

102.

White, J. G. (1972). Exocytosis of secretory organelles from blood platelets incubated with cationic polypeptides. The American Journal of Pathology, 69(1), 41–54.PubMedPubMedCentral

103.

White, J. G., & Estensen, R. D. (1972). Degranulation of discoid platelets. The American Journal of Pathology, 68(2), 289–302.PubMedPubMedCentral

104.

Harrison, P., & Cramer, E. M. (1993). Platelet alpha-granules. Blood Reviews, 7(1), 52–62.PubMedCrossRef

105.

Yadav, S., & Storrie, B. (2017). The cellular basis of platelet secretion: emerging structure/function relationships. Platelets, 28(2), 108–118. doi:10.1080/09537104.2016.1257786.PubMedCrossRef

106.

Sander, H. J., Slot, J. W., Bouma, B. N., Bolhuis, P. A., Pepper, D. S., & Sixma, J. J. (1983). Immunocytochemical localization of fibrinogen, platelet factor 4, and beta thromboglobulin in thin frozen sections of human blood platelets. The Journal of Clinical Investigation, 72(4), 1277–1287. doi:10.1172/jci111084.PubMedPubMedCentralCrossRef

107.

Wencel-Drake, J. D., Painter, R. G., Zimmerman, T. S., & Ginsberg, M. H. (1985). Ultrastructural localization of human platelet thrombospondin, fibrinogen, fibronectin, and von Willebrand factor in frozen thin section. Blood, 65(4), 929–938.PubMed

108.

White, J. G. (1968). The dense bodies of human platelets. Origin of serotonin storage particles from platelet granules. The American Journal of Pathology, 53(5), 791–808.PubMedPubMedCentral

109.

Flaumenhaft, R. (2006). Formation and fate of platelet microparticles. Blood Cells, Molecules & Diseases, 36(2), 182–187. doi:10.1016/j.bcmd.2005.12.019.CrossRef

110.

Horstman, L. L., & Ahn, Y. S. (1999). Platelet microparticles: a wide-angle perspective. Critical Reviews in Oncology/Hematology, 30(2), 111–142.PubMedCrossRef

111.

Wolf, P. (1967). The nature and significance of platelet products in human plasma. British Journal of Haematology, 13(3), 269–288.PubMedCrossRef

112.

Heijnen, H. F., Schiel, A. E., Fijnheer, R., Geuze, H. J., & Sixma, J. J. (1999). Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood, 94(11), 3791–3799.PubMed

113.

Zmigrodzka, M., Guzera, M., Miskiewicz, A., Jagielski, D., & Winnicka, A. (2016). The biology of extracellular vesicles with focus on platelet microparticles and their role in cancer development and progression. Tumour Biology, 37(11), 14391–14401. doi:10.1007/s13277-016-5358-6.PubMedPubMedCentralCrossRef

114.

Janowska-Wieczorek, A., Wysoczynski, M., Kijowski, J., Marquez-Curtis, L., Machalinski, B., Ratajczak, J., et al. (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. International Journal of Cancer, 113(5), 752–760. doi:10.1002/ijc.20657.PubMedCrossRef

115.

Hugel, B., Martinez, M. C., Kunzelmann, C., & Freyssinet, J. M. (2005). Membrane microparticles: two sides of the coin. Physiology (Bethesda), 20, 22–27. doi:10.1152/physiol.00029.2004.CrossRef

116.

Bobrie, A., Colombo, M., Raposo, G., & Thery, C. (2011). Exosome secretion: molecular mechanisms and roles in immune responses. Traffic, 12(12), 1659–1668. doi:10.1111/j.1600-0854.2011.01225.x.PubMedCrossRef

117.

Varon, D., & Shai, E. (2009). Role of platelet-derived microparticles in angiogenesis and tumor progression. Discovery Medicine, 8(43), 237–241.PubMed

118.

Dovizio, M., Alberti, S., Guillem-Llobat, P., & Patrignani, P. (2014). Role of platelets in inflammation and cancer: novel therapeutic strategies. Basic & Clinical Pharmacology & Toxicology, 114(1), 118–127. doi:10.1111/bcpt.12156.CrossRef

119.

Mause, S. F., & Weber, C. (2010). Microparticles: protagonists of a novel communication network for intercellular information exchange. Circulation Research, 107(9), 1047–1057. doi:10.1161/circresaha.110.226456.PubMedCrossRef

120.

Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., & Lotvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 9(6), 654–659. doi:10.1038/ncb1596.PubMedCrossRef

121.

Weidle, U. H., Birzele, F., Kollmorgen, G., & Ruger, R. (2017). The multiple roles of exosomes in metastasis. Cancer Genomics Proteomics, 14(1), 1–15. doi:10.21873/cgp.20015.PubMedCrossRef

122.

Chaput, N., & Thery, C. (2011). Exosomes: immune properties and potential clinical implementations. Seminars in Immunopathology, 33(5), 419–440. doi:10.1007/s00281-010-0233-9.PubMedCrossRef

123.

Thery, C., Zitvogel, L., & Amigorena, S. (2002). Exosomes: composition, biogenesis and function. Nature Reviews. Immunology, 2(8), 569–579. doi:10.1038/nri855.PubMed

124.

Thery, C., Boussac, M., Veron, P., Ricciardi-Castagnoli, P., Raposo, G., Garin, J., et al. (2001). Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. Journal of Immunology, 166(12), 7309–7318.CrossRef

125.

Honn, K. V., Tang, D. G., & Chen, Y. Q. (1992). Platelets and cancer metastasis: more than an epiphenomenon. Seminars in Thrombosis and Hemostasis, 18(4), 392–415. doi:10.1055/s-2007-1002578.PubMedCrossRef

126.

Zucker, S., Pei, D., Cao, J., & Lopez-Otin, C. (2003). Membrane type-matrix metalloproteinases (MT-MMP). Current Topics in Developmental Biology, 54, 1–74.PubMedCrossRef

127.

Jansen, F., Yang, X., Hoyer, F. F., Paul, K., Heiermann, N., Becher, M. U., et al. (2012). Endothelial microparticle uptake in target cells is annexin I/phosphatidylserine receptor dependent and prevents apoptosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(8), 1925–1935. doi:10.1161/atvbaha.112.253229.PubMedCrossRef

128.

Ciravolo, V., Huber, V., Ghedini, G. C., Venturelli, E., Bianchi, F., Campiglio, M., et al. (2012). Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. Journal of Cellular Physiology, 227(2), 658–667. doi:10.1002/jcp.22773.PubMedCrossRef

129.

Helley, D., Banu, E., Bouziane, A., Banu, A., Scotte, F., Fischer, A. M., et al. (2009). Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. European Urology, 56(3), 479–484. doi:10.1016/j.eururo.2008.06.038.PubMedCrossRef

130.

Kim, H. K., Song, K. S., Park, Y. S., Kang, Y. H., Lee, Y. J., Lee, K. R., et al. (2003). Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. European Journal of Cancer, 39(2), 184–191.PubMedCrossRef

131.

Italiano Jr., J. E., Mairuhu, A. T., & Flaumenhaft, R. (2010). Clinical relevance of microparticles from platelets and megakaryocytes. Current Opinion in Hematology, 17(6), 578–584. doi:10.1097/MOH.0b013e32833e77ee.PubMedPubMedCentralCrossRef

132.

Kral, J. B., Schrottmaier, W. C., Salzmann, M., & Assinger, A. (2016). Platelet interaction with innate immune cells. Transfusion Medicine and Hemotherapy, 43(2), 78–88. doi:10.1159/000444807.PubMedPubMedCentralCrossRef

133.

Manne, B. K., Xiang, S. C., & Rondina, M. T. (2017). Platelet secretion in inflammatory and infectious diseases. Platelets, 28(2), 155–164. doi:10.1080/09537104.2016.1240766.PubMedCrossRef

134.

Thomas, M. R., & Storey, R. F. (2015). The role of platelets in inflammation. Thrombosis and Haemostasis, 114(3), 449–458. doi:10.1160/TH14-12-1067.PubMedCrossRef

135.

Laurance, S., Bertin, F. R., Ebrahimian, T., Kassim, Y., Rys, R. N., Lehoux, S., et al. (2017). Gas6 (growth arrest-specific 6) promotes inflammatory (CCR2hiCX3CR1lo) monocyte recruitment in venous thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology. doi:10.1161/ATVBAHA.116.308925.

136.

Frydman, G. H., Le, A., Ellett, F., Jorgensen, J., Fox, J. G., Tompkins, R. G., et al. (2017). Technical advance: changes in neutrophil migration patterns upon contact with platelets in a microfluidic assay. Journal of Leukocyte Biology, 101(3), 797–806. doi:10.1189/jlb.1TA1115-517RR.PubMedCrossRef

137.

Zuchtriegel, G., Uhl, B., Puhr-Westerheide, D., Pornbacher, M., Lauber, K., Krombach, F., et al. (2016). Platelets guide leukocytes to their sites of extravasation. PLoS Biology, 14(5), e1002459. doi:10.1371/journal.pbio.1002459.PubMedPubMedCentralCrossRef

138.

Yan, M., & Jurasz, P. (2016). The role of platelets in the tumor microenvironment: from solid tumors to leukemia. Biochimica et Biophysica Acta, 1863(3), 392–400. doi:10.1016/j.bbamcr.2015.07.008.PubMedCrossRef

139.

Kim, J., & Bae, J. S. (2016). Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators of Inflammation, 2016, 6058147. doi:10.1155/2016/6058147.PubMedPubMedCentral

140.

Rossaint, J., & Zarbock, A. (2015). Platelets in leucocyte recruitment and function. Cardiovascular Research, 107(3), 386–395. doi:10.1093/cvr/cvv048.PubMedCrossRef

141.

Dohlman, T. H., Di Zazzo, A., Omoto, M., Hua, J., Ding, J., Hamrah, P., et al. (2016). E-selectin mediates immune cell trafficking in corneal transplantation. Transplantation, 100(4), 772–780. doi:10.1097/TP.0000000000001107.PubMedPubMedCentralCrossRef

142.

Dinkla, S., van Cranenbroek, B., van der Heijden, W. A., He, X., Wallbrecher, R., Dumitriu, I. E., et al. (2016). Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin. Blood, 127(16), 1976–1986. doi:10.1182/blood-2015-04-640300.PubMedCrossRef

143.

Scotland, R. S., Cohen, M., Foster, P., Lovell, M., Mathur, A., Ahluwalia, A., et al. (2005). C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proceedings of the National Academy of Sciences of the United States of America, 102(40), 14452–14457. doi:10.1073/pnas.0504961102.PubMedPubMedCentralCrossRef

144.

Diacovo, T. G., Roth, S. J., Morita, C. T., Rosat, J. P., Brenner, M. B., & Springer, T. A. (1996). Interactions of human alpha/beta and gamma/delta T lymphocyte subsets in shear flow with E-selectin and P-selectin. The Journal of Experimental Medicine, 183(3), 1193–1203.PubMedCrossRef

145.

Hu, M., Zhang, H., Liu, Q., & Hao, Q. (2016). Structural basis for human PECAM-1-mediated trans-homophilic cell adhesion. Scientific Reports, 6, 38655. doi:10.1038/srep38655.PubMedPubMedCentralCrossRef

146.

Vachino, G., Chang, X. J., Veldman, G. M., Kumar, R., Sako, D., Fouser, L. A., et al. (1995). P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells. The Journal of Biological Chemistry, 270(37), 21966–21974.PubMedCrossRef

147.

Duchez, A. C., Boudreau, L. H., Naika, G. S., Bollinger, J., Belleannee, C., Cloutier, N., et al. (2015). Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA. Proceedings of the National Academy of Sciences of the United States of America, 112(27), E3564–E3573. doi:10.1073/pnas.1507905112.PubMedPubMedCentralCrossRef

148.

Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews. Cancer, 11(2), 123–134. doi:10.1038/nrc3004.PubMedCrossRef

149.

Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, K. W., et al. (2005). Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood, 105(1), 178–185. doi:10.1182/blood-2004-06-2272.PubMedCrossRef

150.

Calverley, D. C., Phang, T. L., Choudhury, Q. G., Gao, B., Oton, A. B., Weyant, M. J., et al. (2010). Significant downregulation of platelet gene expression in metastatic lung cancer. Clinical and Translational Science, 3(5), 227–232.PubMedPubMedCentralCrossRef

151.

Nilsson, R. J., Balaj, L., Hulleman, E., van Rijn, S., Pegtel, D. M., Walraven, M., et al. (2011). Blood platelets contain tumor-derived RNA biomarkers. Blood, 118(13), 3680–3683. doi:10.1182/blood-2011-03-344408.PubMedCrossRef

152.

Joosse, S. A., & Pantel, K. (2015). Tumor-educated platelets as liquid biopsy in cancer patients. Cancer Cell, 28(5), 552–554. doi:10.1016/j.ccell.2015.10.007.PubMedCrossRef

153.

Best, M. G., Sol, N., Kooi, I., Tannous, J., Westerman, B. A., Rustenburg, F., et al. (2015). RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell, 28(5), 666–676. doi:10.1016/j.ccell.2015.09.018.PubMedPubMedCentralCrossRef

154.

Zhu, J., & Strickler, J. H. (2016). Clinical applications of liquid biopsies in gastrointestinal oncology. J Gastrointest Oncol, 7(5), 675–686. doi:10.21037/jgo.2016.08.08.PubMedPubMedCentralCrossRef

155.

Feller, S. M., & Lewitzky, M. (2016). Hunting for the ultimate liquid cancer biopsy—let the TEP dance begin. Cell Communication and Signaling: CCS, 14(1), 24. doi:10.1186/s12964-016-0147-9.PubMedCentralCrossRef

156.

Holmes, C. E., Levis, J. E., Schneider, D. J., Bambace, N. M., Sharma, D., Lal, I., et al. (2016). Platelet phenotype changes associated with breast cancer and its treatment. Platelets, 27(7), 703–711. doi:10.3109/09537104.2016.1171302.PubMedCrossRef

157.

Dixon, D. A., Tolley, N. D., Bemis-Standoli, K., Martinez, M. L., Weyrich, A. S., Morrow, J. D., et al. (2006). Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. The Journal of Clinical Investigation, 116(10), 2727–2738. doi:10.1172/jci27209.PubMedPubMedCentralCrossRef

158.

Evangelista, V., Manarini, S., Di Santo, A., Capone, M. L., Ricciotti, E., Di Francesco, L., et al. (2006). De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circulation Research, 98(5), 593–595. doi:10.1161/01.RES.0000214553.37930.3e.PubMedCrossRef

159.

Guillem-Llobat, P., Dovizio, M., Alberti, S., Bruno, A., & Patrignani, P. (2014). Platelets, cyclooxygenases, and colon cancer. Seminars in Oncology, 41(3), 385–396. doi:10.1053/j.seminoncol.2014.04.008.PubMedCrossRef

160.

Mitrugno, A., Sylman, J. L., Ngo, A. T., Pang, J., Sears, R. C., Williams, C. D., et al. (2017). Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC. American Journal of Physiology. Cell Physiology, 312(2), C176–c189. doi:10.1152/ajpcell.00196.2016.PubMedCrossRef

161.

Radziwon-Balicka, A., Santos-Martinez, M. J., Corbalan, J. J., O'Sullivan, S., Treumann, A., Gilmer, J. F., et al. (2014). Mechanisms of platelet-stimulated colon cancer invasion: role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway. Carcinogenesis, 35(2), 324–332. doi:10.1093/carcin/bgt332.PubMedCrossRef

162.

Labelle, M., Begum, S., & Hynes, R. O. (2011). Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell, 20(5), 576–590. doi:10.1016/j.ccr.2011.09.009.PubMedPubMedCentralCrossRef

163.

Cooke, N. M., Spillane, C. D., Sheils, O., O'Leary, J., & Kenny, D. (2015). Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion. BMC Cancer, 15, 627. doi:10.1186/s12885-015-1634-x.PubMedPubMedCentralCrossRef

164.

Mammadova-Bach, E., Zigrino, P., Brucker, C., Bourdon, C., Freund, M., De Arcangelis, A., et al. (2016). Platelet integrin alpha6beta1 controls lung metastasis through direct binding to cancer cell-derived ADAM9. JCI Insight, 1(14), e88245. doi:10.1172/jci.insight.88245.PubMedPubMedCentralCrossRef

165.

Menter, D. G., Onoda, J. M., Taylor, J. D., & Honn, K. V. (1984). Effects of prostacyclin on tumor cell-induced platelet aggregation. Cancer Research, 44(2), 450–456.PubMed

166.

Menter, D. G., Harkins, C., Onoda, J., Riorden, W., Sloane, B. F., Taylor, J. D., et al. (1987). Inhibition of tumor cell induced platelet aggregation by prostacyclin and carbacyclin: an ultrastructural study. Invasion & Metastasis, 7(2), 109–128.

167.

Gasic, G. J., & Gasic, T. B. (1982). Plasma membrane vesicles as mediators of interactions between tumor cells and components of the hemostatic and immune systems. Progress in Clinical and Biological Research, 89, 429–444.PubMed

168.

Gasic, G. J., Tuszynski, G. P., & Gorelik, E. (1986). Interaction of the hemostatic and immune systems in the metastatic spread of tumor cells. International Review of Experimental Pathology, 29, 173–212.PubMedCrossRef

169.

Ruppert, M., Aigner, S., Hubbe, M., Yagita, H., & Altevogt, P. (1995). The L1 adhesion molecule is a cellular ligand for VLA-5. The Journal of Cell Biology, 131(6 Pt 2), 1881–1891.PubMedCrossRef

170.

Tsuruo, T., & Fujita, N. (2008). Platelet aggregation in the formation of tumor metastasis. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 84(6), 189–198.PubMedPubMedCentralCrossRef

171.

Menter, D. G., Steinert, B. W., Sloane, B. F., Taylor, J. D., & Honn, K. V. (1987). A new in vitro model for investigation of tumor cell-platelet-endothelial cell interactions and concomitant eicosanoid biosynthesis. Cancer Research, 47(9), 2425–2432.PubMed

172.

Menter, D. G., Onoda, J. M., Moilanen, D., Sloane, B. F., Taylor, J. D., & Honn, K. V. (1987). Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation. Journal of the National Cancer Institute, 78(5), 961–969.PubMed

173.

Xu, L., Mao, X., Imrali, A., Syed, F., Mutsvangwa, K., Berney, D., et al. (2015). Optimization and evaluation of a novel size based circulating tumor cell isolation system. PloS One, 10(9), e0138032. doi:10.1371/journal.pone.0138032.PubMedPubMedCentralCrossRef

174.

Sorensen, H. T., Mellemkjaer, L., Steffensen, F. H., Olsen, J. H., & Nielsen, G. L. (1998). The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. The New England Journal of Medicine, 338(17), 1169–1173. doi:10.1056/nejm199804233381701.PubMedCrossRef

175.

Levitan, N., Dowlati, A., Remick, S. C., Tahsildar, H. I., Sivinski, L. D., Beyth, R., et al. (1999). Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore), 78(5), 285–291.CrossRef

176.

Alexandrakis, M. G., Passam, F. H., Moschandrea, I. A., Christophoridou, A. V., Pappa, C. A., Coulocheri, S. A., et al. (2003). Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. American Journal of Clinical Oncology, 26(2), 135–140. doi:10.1097/01.coc.0000017093.79897.de.PubMedCrossRef

177.

Seretis, C., Youssef, H., & Chapman, M. (2015). Hypercoagulation in colorectal cancer: what can platelet indices tell us? Platelets, 26(2), 114–118. doi:10.3109/09537104.2014.894969.PubMedCrossRef

178.

Karagöz, B., Sücüllü, İ., Sayan, Ö., Bilgi, O., Tuncel, T., Filiz, A. İ., et al. (2010). Platelet indices in patients with colorectal cancer. [journal article]. Central European Journal of Medicine, 5(3), 365–368. doi:10.2478/s11536-009-0077-7.

179.

Watt, D. G., Proctor, M. J., Park, J. H., Horgan, P. G., & McMillan, D. C. (2015). The neutrophil-platelet score (NPS) predicts survival in primary operable colorectal cancer and a variety of common cancers. PloS One, 10(11), e0142159. doi:10.1371/journal.pone.0142159.PubMedPubMedCentralCrossRef

180.

Wan, S., Lai, Y., Myers, R. E., Li, B., Hyslop, T., London, J., et al. (2013). Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. Journal of Gastrointestinal Cancer, 44(3), 293–304. doi:10.1007/s12029-013-9491-9.PubMedPubMedCentralCrossRef

181.

Zhao, J. M., Wang, Y. H., Yao, N., Wei, K. K., Jiang, L., Hanif, S., et al. (2016). Poor prognosis significance of pretreatment thrombocytosis in patients with colorectal cancer: a meta-analysis. Asian Pacific Journal of Cancer Prevention, 17(9), 4295–4300.PubMed

182.

Wodarczyk, M., Kasprzyk, J., Sobolewska-Wodarczyk, A., Wodarczyk, J., Tchorzewski, M., Dziki, A., et al. (2016). Mean platelet volume as a possible biomarker of tumor progression in rectal cancer. Cancer Biomarkers, 17(4), 411–417. doi:10.3233/cbm-160657.PubMedCrossRef

183.

Dymicka-Piekarska, V., Matowicka-Karna, J., Osada, J., Kemona, H., & Butkiewicz, A. M. (2006). Changes in platelet CD 62P expression and soluble P-selectin concentration in surgically treated colorectal carcinoma. Advances in Medical Sciences, 51, 304–308.PubMed

184.

Dymicka-Piekarska, V., Kemona, H., Piotrowski, Z., Gryko, M., Milewski, Z., & Matowicka-Karna, J. (2003). Does colorectal cancer influence platelet activation? Przegla̧d Lekarski, 60(11), 716–718.PubMed

185.

Del Rio, M., Mollevi, C., Vezzio-Vie, N., Bibeau, F., Ychou, M., & Martineau, P. (2013). Specific extracellular matrix remodeling signature of colon hepatic metastases. PloS One, 8(9), e74599. doi:10.1371/journal.pone.0074599.PubMedPubMedCentralCrossRef

186.

Zhao, L., Bi, Y., Kou, J., Shi, J., & Piao, D. (2016). Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients. Journal of Experimental & Clinical Cancer Research, 35, 54. doi:10.1186/s13046-016-0328-9.CrossRef

187.

Mantur, M., Snarska, J., Sidorska, A., Ostrowska, H., Kruszewska-Wnorowska, K., & Wojszel, J. (2008). Changes in PDGF concentration in surgically treated colorectal carcinoma. Advances in Medical Sciences, 53(1), 37–41. doi:10.2478/v10039-008-0030-z.PubMedCrossRef

188.

Ogino, S., Kirkner, G. J., Nosho, K., Irahara, N., Kure, S., Shima, K., et al. (2008). Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clinical Cancer Research, 14(24), 8221–8227. doi:10.1158/1078-0432.ccr-08-1841.PubMedPubMedCentralCrossRef

189.

Sharma, D., Brummel-Ziedins, K. E., Bouchard, B. A., & Holmes, C. E. (2014). Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. Journal of Cellular Physiology, 229(8), 1005–1015. doi:10.1002/jcp.24539.PubMedCrossRef

190.

Sostres, C., Gargallo, C. J., & Lanas, A. (2014). Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther, 5(1), 40–49. doi:10.4292/wjgpt.v5.i1.40.PubMedPubMedCentralCrossRef

191.

Su, B. B., Chen, J. H., Shi, H., Chen, Q. Q., & Wan, J. (2014). Aspirin may modify tumor microenvironment via antiplatelet effect. Medical Hypotheses, 83(2), 148–150. doi:10.1016/j.mehy.2014.05.007.PubMedCrossRef

192.

Guillem-Llobat, P., Dovizio, M., Bruno, A., Ricciotti, E., Cufino, V., Sacco, A., et al. (2016). Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget, 7(22), 32462–32477. doi:10.18632/oncotarget.8655.PubMedPubMedCentralCrossRef

193.

Roop, R. P., Naughton, M. J., Van Poznak, C., Schneider, J. G., Lammers, P. E., Pluard, T. J., et al. (2013). A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. Clinical Breast Cancer, 13(6), 409–415. doi:10.1016/j.clbc.2013.08.006.PubMedPubMedCentralCrossRef

194.

Holmes, C. E., Jasielec, J., Levis, J. E., Skelly, J., & Muss, H. B. (2013). Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. Clinical and Translational Science, 6(5), 386–390. doi:10.1111/cts.12070.PubMedPubMedCentralCrossRef

195.

Thun, M. J., Henley, S. J., & Patrono, C. (2002). Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. Journal of the National Cancer Institute, 94(4), 252–266.PubMedCrossRef

196.

Alonso-Escolano, D., Strongin, A. Y., Chung, A. W., Deryugina, E. I., & Radomski, M. W. (2004). Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. British Journal of Pharmacology, 141(2), 241–252. doi:10.1038/sj.bjp.0705606.PubMedCrossRef

197.

Frouws, M. A., Rademaker, E., Bastiaannet, E., van Herk-Sukel, M. P., Lemmens, V. E., Van de Velde, C. J., et al. (2017). The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer. European Journal of Cancer, 77, 24–30. doi:10.1016/j.ejca.2017.02.025.PubMedCrossRef

198.

Liang, H., Yang, C., Zhang, B., Wang, H., Liu, H., Zhao, Z., et al. (2015). Hydroxyethyl starch 200/0.5 decreases circulating tumor cells of colorectal cancer patients and reduces metastatic potential of colon cancer cell line through inhibiting platelets activation. Medical Oncology, 32(5), 151. doi:10.1007/s12032-015-0601-3.PubMedCrossRef

199.

Zhang, Y., Wei, J., Liu, S., Wang, J., Han, X., Qin, H., et al. (2017). Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics, 7(5), 1062–1071. doi:10.7150/thno.17908.PubMedPubMedCentralCrossRef

200.

Ludwig, R. J., Schon, M. P., & Boehncke, W. H. (2007). P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Expert Opinion on Therapeutic Targets, 11(8), 1103–1117. doi:10.1517/14728222.11.8.1103.PubMedCrossRef

201.

Qi, C., Li, B., Guo, S., Wei, B., Shao, C., Li, J., et al. (2015). P-selectin-mediated adhesion between platelets and tumor cells promotes intestinal tumorigenesis in Apc(min/+) mice. International Journal of Biological Sciences, 11(6), 679–687. doi:10.7150/ijbs.11589.PubMedPubMedCentralCrossRef

202.

Dymicka-Piekarska, V., Butkiewicz, A., Matowicka-Karna, J., & Kemona, H. (2005). Soluble P-selectin concentration in patients with colorectal cancer. Neoplasma, 52(4), 297–301.PubMed

203.

Dymicka-Piekarska, V., Matowicka-Karna, J., Gryko, M., Kemona-Chetnik, I., & Kemona, H. (2007). Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. Thrombosis Research, 120(4), 585–590. doi:10.1016/j.thromres.2006.11.002.PubMedCrossRef

204.

Li, J., Sharkey, C. C., Wun, B., Liesveld, J. L., & King, M. R. (2016). Genetic engineering of platelets to neutralize circulating tumor cells. Journal of Controlled Release, 228, 38–47. doi:10.1016/j.jconrel.2016.02.036.PubMedPubMedCentralCrossRef

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Platelets, circulating tumor cells, and the circulome

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Platelet RNA signatures for the detection of cancer

Cytokine-induced senescence for cancer surveillance

Platelet “first responders” in wound response, cancer, and metastasis

Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?